Results 21 to 30 of about 4,245 (206)

Somatostatin receptor saturation after administration of high peptide amounts of [177Lu]Lu-HA-DOTATATE: when enough is enough

EJNMMI Research, 2022
Background Receptor saturation during peptide receptor radionuclide therapy (PRRT) could result in altered [177Lu]Lu-HA-DOTATATE uptake in tumors and organs.
Hinke Siebinga, Chayenne H. A. M. Veerman, Linda de Wit-van der Veen, Marcel P. M. Stokkel, Jeroen J. M. A. Hendrikx, Else A. Aalbersberg   +5 more
doaj   +1 more source

Challenges in Von Hippel–Lindau’s disease: PRRT in patients on hemodialysis

Endocrinology, Diabetes & Metabolism Case Reports, 2022
Von Hippel–Lindau’s disease (VHL) is a hereditary tumor syndrome characterized by its prototype lesions, hemangioblastomas, and renal cell carcinomas. Treatment for renal cell carcinomas can ultimately result in long-term dialysis.
N Ayub, A J A T Braat, H J L M Timmers, M G E H Lam, R S van Leeuwaarde   +4 more
doaj   +1 more source

Peptide Receptor Radionuclide Therapy Targeting the Somatostatin Receptor: Basic Principles, Clinical Applications and Optimization Strategies

, 2021
Peptide receptor radionuclide therapy (PRRT) consists of the administration of a tumor-targeting radiopharmaceutical into the circulation of a patient. The radiopharmaceutical will bind to a specific peptide receptor leading to tumor-specific binding and
Van Cutsem, Eric, Jeroen Dekervel, Dekervel, Jeroen, Eric Van Cutsem, Kristof Baete, Deroose, Christophe M., Baete, Kristof, Kristiaan Nackaerts, Paul Clement, Niloefar Ahmadi Bidakhvidi, Verslype, Chris, Christophe M. Deroose, Clement, Paul, Ahmadi Bidakhvidi, Niloefar, Karolien Goffin, Chris Verslype, Goffin, Karolien, Nackaerts, Kristiaan   +17 more
core   +1 more source

Responses to medical treatment in patients with metastatic unresectable small intestinal neuroendocrine tumors - A single center study of 378 patients. [PDF]

J Neuroendocrinol
Abstract Small intestinal neuroendocrine tumors (siNET) are rare malignancies, often diagnosed at advanced stages with metastatic spread. While surgery is the only curative treatment, medical therapies, including somatostatin analogues (SSA), peptide receptor radionuclide therapy (PRRT), and other systemic treatments, are essential for disease ...
Slott C, Langer SW, Oturai P, Møller S, Hansen CP, Kjaer A, Holmager P, Klose M, Garbyal RS, Knigge U, Andreassen M.   +10 more
europepmc   +2 more sources

Strategies Towards Improving Clinical Outcomes of Peptide Receptor Radionuclide Therapy [PDF]

, 2021
Purpose of Review: Peptide receptor radionuclide therapy (PRRT) with [177Lu-DOTA0,Tyr3] octreotate is an effective and safe second- or third-line treatment option for patients with low-grade advanced gastroenteropancreatic (GEP) neuroendocrine neoplasms (
Minczeles, N. S., Hofland, J., Brabander, T., de Herder, W. W.   +3 more
core   +1 more source

Peptide Receptor Radionuclide Therapy for a Phosphaturic Mesenchymal Tumor. [PDF]

, 2020
Tumor-induced osteomalacia is a very rare paraneoplastic syndrome. It can be caused by phosphaturic mesenchymal tumor (PMT), a generally benign tumor that produces fibroblast growth factor 23 (FGF-23), which can cause a severe renal phosphate wasting ...
Steinmann-Schwager, Stephanie, Häfliger, Simon, Schoch, Eric, Wild, Damian, Reichmann, Jan, Pless, Miklos, Seidel, Ann-Katrin   +6 more
core   +1 more source

The effects of peptide receptor radionuclide therapy on the neoplastic and normal pituitary [PDF]

, 2023
Pituitary neuroendocrine tumours (PitNETs) are usually benign and slow-growing; how- ever, in some cases, they may behave aggressively and become resistant to conventional treatments.
Pedro Marques, Marques, Pedro
core   +1 more source

Combination of [¹⁷⁷Lu]Lu-DOTA-TATE Targeted Radionuclide Therapy and Photothermal Therapy as a Promising Approach for Cancer Treatment: In Vivo Studies in a Human Xenograft Mouse Model

Pharmaceutics, 2022
Peptide receptor radionuclide therapy (PRRT) relies on α- and β-emitting radionuclides bound to a peptide that commonly targets somatostatin receptors (SSTRs) for the localized killing of tumors through ionizing radiation.
Marina Simón, Jesper Tranekjær Jørgensen, Harshvardhan A. Khare, Camilla Christensen, Carsten Haagen Nielsen, Andreas Kjaer   +5 more
doaj   +1 more source

Peptide Receptor Radionuclide Therapy (PRRT) in a Patient Affected by Metastatic Breast Cancer with Neuroendocrine Differentiation [PDF]

Breast Care, 2012
Breast cancer (BC) is the most frequent cancer in European women with nearly 30% of the patients eventually developing metastases. Neuroendocrine differentiation is a rare event, but overexpression of somatostatin receptors in BC has been reported in many studies.A patient with liver metastases from BC was treated with peptide receptor radionuclide ...
Giordano Savelli, Alberto Zaniboni, BERTAGNA, Francesco, Giovanni Bosio, Lutfun Nisa, Carlo Rodella, BIASIOTTO, Giorgio, Giovanni Bettinsoli, Elena Migliorati, Alessia Peli, Roberta Falchi, Francesca Giuffrida, GIUBBINI, Raffaele   +12 more
openaire   +2 more sources

Induction of Anti-Tumor Immune Responses by Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in a Murine Model of a Human Neuroendocrine Tumor

Diagnostics, 2013
Peptide receptor radionuclide therapy (PRRT) is a relatively new mode of internally targeted radiotherapy currently in clinical trials. In PRRT, ionizing radioisotopes conjugated to somatostatin analogues are targeted to neuroendocrine tumors (NETs) via ...
Michael Bzorek, Michael Holmsgaard Kristensen, Andreas Kjaer, Andreas Klaus Pfeifer, Ulrich Knigge, Yin Wu, Rajendra Singh Garbyal, Palle Rasmussen, Rebecca Myschetzky   +8 more
doaj   +1 more source